Clinical Trials Browser

Lymphoma, T-Cell × tenalisib × Clear all

NCT03770000 2022-10-28

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Phase 1/2 Completed

33 enrolled 13 charts

Lymphoma, T-Cell

NCT02017613 2016-06-24

PI3K

Phase 1 Completed

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous